|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
�����ҩ |
|
�������� |
|
�������� |
|
���� |
|
�������� |
|
��ŵ���� |
| ��������������� | |
|
�»� |
|
���� |
| PubMed | |
|
Article by |
|
Article by |
���ֹ��ڼ������е����ÿ����ҩ����
�»�, ��ά��
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о��������, �Ͼ�210042
��20����,�����ҩ����о���չѸ��,����Ҳ�ڻ������ơ������µĿ����ҩ���Ҫ�����˼��ֹ������ڱ������������е����ÿ����ҩ������û��ơ��������Լ��ٴ�Ӧ�á�
[2] Oku Y, Sakuma K, Yokoyama K, et al. Fungicidal activity of liranaftate against Trichophyton rubrum. Nippon Ishinkin Gakkai Zasshi,2002, 43:181-187.
[3] Takahashi H. Phase �� controlled trial of M-732(liranaftate) cream in patients with tinea cruris evaluating with In vitro incubation results.Nishinippon Hifuka(Nishinihon J Dermatol), 2000,62:788-802.
[4] Gebhart R J, Espinel-Ingroff A, Shadomy S. In vitro susceptibility studies with oxiconazole (Ro 13-8996). Chemotherapy, 1984,30:244-247.
[5] Jegasothy BV, Pakes GE. Oxiconazole nitrate:pharmacology, efficacy, and safety of a new imidasole antifungal agent. Clin Ther, 1991,13:126-141.
[6] Raulin C, Frosch PJ. Contact allergy to oxiconazole. Contact Dermatitis, 1987, 16:39-40.
[7] Hernandez Molina JM, Llosa J, Martinez Brocal A, et al. In vitro activity of cloconazole, sulconazole, butoconazole, isoconazole, fenticonazole, and five other antifungal agents against clinical isolates of Candida albicans and Candida spp. Mycopathologia, 1992, 118:15-21.
[8] Gugnani HC, Gugnani A, Malachy O. Sulconazole in the therapy of dermatomycoses in Nigeria. Mycoses, 1997, 40:139-t41.
[9] Bigardi AS, Pigatto PD, Altomare G. Allergic contact dermatitis due to sulconazole. Contact Dermatitis, 1992, 26:281-282.
[10] Agut J, Palacin C, Salgado J, et al. Direct membrane-damaging effect of sertaconazole on Candida albicans as a mechanism of its fungicidal activity. Arzneimittelforschung, 1992, 42:721-724.
[11] Carrillo-Munoz A J, Fernandez-Torres B, Guano J. In vitro antifungal activity of sertaconazole against 309 dermatophyte clinical isolates. J Chemother, 2003, 15:555-557.
[12] Carrillo-Munoz AJ, Fernandez-Torres B, Cardenes DC, et al. In vitro activity of sertaconazole against dermatophyte isolates with reduced fluconazole susceptibility. Chemotherapy, 2003, 49:248-251.
[13] Carrillo-Munoz AJ, Brio S, Quindos G, et al. Sertaconazole:in-vitro antifungal activity against vaginal and other superficial yeast isolates. J Chemother, 2001, 13:555-562.
[14] Palacin C, Tarrago C, Agut J, et al. In vitro activity of sertaconazole,fluconazole, ketoconazole, fenticonazole, clotrimazole and itraconazole against pathogenic vaginal yeast isolates. Methods Find Exp Clin Pharmacol, 2001,23:61-64.
[15] Dellenbach P, Thomas JL, Guerin V, et al. Topical treatment of vaginal candidosis with sertaconasole and econazole sustained-release suppositories. Int J Gynaecol Obstet, 2000, 71:S47-S52.
[16] Quereux C, Gelas B, Chevallier T, et al. Evaluation of the efficacity and speed of action of sertaconazole nitrate suppository and cream combined treatment for vulvovaginal candidiasis. Gynecol Obstet Fertil, 2000, 28:238-244.
[17] Alomar C, Bassas S, Casas M, et al. Multi-centre double-blind trial on the efficacy and safety of sertaconazole 2% cream in comparison with miconazole 2% cream on patients suffering from cutaneous mycoses. Arzneimittelforschung, 1992, 42:767-773.
[18] Tatsumi Y, Yokoo M, Arika T,et al. In vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs. Antimicrob Agents Chemother, 2001,45:1493-1499.
[19] Uchida K, Nishiyama Y, Tanaka T, et al. In vitro activity of novel imidazole antifungal agent NND-502 against Malassezia species. Int J Antimicrob Agents, 2003, 21:234-238.
[20] Niwano Y, Tabuchi T, Kanai K, et al. Short-term topical therapy of experimental tinea pedis in guinea pigs with lanoconazole, a new imidazole antimycotic agent. Antimicrob Agents Chemother, 1995, 39:2353-2355.
[21] Tanuma H, Tanuma M, Abe M, et al. Usefulness of lanoconazole (Astat) cream in the treatment of hyperkeratotic type tinea pedis.Comparative study of monotherapy and combination therapy with 10% urea ointment (Pastaron). Mycoses, 2001,44:181-190.
[22] Niwano Y, Koga H, Kanai K, et al. Wound healing effect of the new imidazole antimycotic lanoconazole in rats. Arzneimittelforschung,1996, 46:218-213.
[23] Soga F, Katoh N, Kishimoto S. Contact dermatitis due to lanoconazole, cetyl alcohol and diethyl sebacate in lanoconazole cream. Contact Dermatitis, 2004, 50:49-50.